 Cell Line, Tumor
"Cell Line, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cell line derived from cultured tumor cells.
| Descriptor ID |
D045744
|
| MeSH Number(s) |
A11.251.210.190 A11.251.860.180
|
| Concept/Terms |
Cell Line, Tumor- Cell Line, Tumor
- Cell Lines, Tumor
- Line, Tumor Cell
- Lines, Tumor Cell
- Tumor Cell Lines
- Tumor Cell Line
|
Below are MeSH descriptors whose meaning is more general than "Cell Line, Tumor".
Below are MeSH descriptors whose meaning is more specific than "Cell Line, Tumor".
This graph shows the total number of publications written about "Cell Line, Tumor" by people in this website by year, and whether "Cell Line, Tumor" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 | | 2002 | 0 | 1 | 1 | | 2003 | 2 | 19 | 21 | | 2004 | 0 | 51 | 51 | | 2005 | 0 | 58 | 58 | | 2006 | 0 | 75 | 75 | | 2007 | 1 | 64 | 65 | | 2008 | 0 | 79 | 79 | | 2009 | 0 | 93 | 93 | | 2010 | 2 | 100 | 102 | | 2011 | 1 | 120 | 121 | | 2012 | 0 | 113 | 113 | | 2013 | 1 | 123 | 124 | | 2014 | 1 | 120 | 121 | | 2015 | 1 | 123 | 124 | | 2016 | 0 | 115 | 115 | | 2017 | 2 | 137 | 139 | | 2018 | 0 | 141 | 141 | | 2019 | 0 | 118 | 118 | | 2020 | 1 | 73 | 74 | | 2021 | 0 | 83 | 83 | | 2022 | 0 | 43 | 43 | | 2023 | 0 | 42 | 42 | | 2024 | 0 | 108 | 108 | | 2025 | 0 | 133 | 133 | | 2026 | 0 | 38 | 38 |
To return to the timeline, click here.
Below are the most recent publications written about "Cell Line, Tumor" by people in Profiles.
-
Yamamoto TM, Iwanaga R, Woodruff ER, Elder AM, Petkov A, Nurmemmedov E, Eisenmesser E, Reigan P, Bitler BG, Brubaker LW. Chromobox 2 Inhibition: A Novel Activity of Alisertib, an Aurora A Kinase Inhibitor. Mol Cancer Ther. 2026 Jul 02; 25(7):1130-1143.
-
Kane GI, Diaz-Infante MB, Wigglesworth K, Lusi E, Brassil M, Rozen EJ, Kady J, Mori H, Lukas J, Naylor T, Dinnell RW, Murphy KC, Alarcon CBB, Ruscetti M, Brehm M, Shohet JM, Atukorale PU. Tumor Homing Nanoparticle Immunotherapy for Acute Clearance and Mitigation of T-cell Exhaustion in Humanized High-Risk Neuroblastoma. Mol Cancer Ther. 2026 Jul 02; 25(7):1144-1156.
-
Chakravorty S, Zybina Y, Ahn E, Pradhan K, Yu N, Taylor M, Charati M, Wilson DC, Jeon AB, Blumenschein WM, Han JH. Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody-Drug Conjugate Payloads. Mol Cancer Ther. 2026 Jun 01; 25(6):976-991.
-
Magno JC, Guo J, Hall SC, Liu J, Albert GK, Carter JD, Davalos AS, Cao P, Bangar A, Drigot Z, Hudson H, Geluck T, Nevala WK, Markovic SN, Wilky BA, Davila E. Engineering T Cells with a Tumor-Reactive Chimeric T-cell Receptor Reduces Exhaustion and Promotes Persistence to Elicit Enhanced Antitumor Responses. Cancer Res. 2026 Jun 01; 86(11):2688-2702.
-
Keane L, ?kandík M, Posada-Pérez M, Bose R, Desito J, van der Linde E, Engskog-Vlachos P, Ceccatelli S, Green AL, Joseph B. Microglia in diffuse midline glioma contribute to extracellular matrix remodelling and cancer cell invasion. Cell Death Dis. 2026 May 30; 17(1).
-
Duval H, Toomey B, Karam M, Braun T, Fournier D, Grant C, Fairfield H, Chepurko V, Chepurko E, Schimelman A, Nestor B, Ryzhov S, Lindner V, Reagan MR. Microenvironmental CTHRC1 has a pro-tumorigenic role in colorectal cancer. Oncotarget. 2026 May 20; 17(1):258-267.
-
Ahmed M, Haneefa SM, Alam A, Kali SK, Al-Sbiei A, Bashir G, Al-Bawardi A, Idriss I, Mohamed YA, Khlaifat B, Naser HT, Labania L, Hamoudi R, Kishore U, Attoub S, Rincon M, Ramadi KB, Fernandez-Cabezudo MJ, Al-Ramadi BK. Modulation of the immunogenic landscape in colorectal cancer by mitochondrial methylation-controlled J protein. Mol Biomed. 2026 May 11; 7(1).
-
Duffy JT, Martin-Regalado A, Haupt BE, Pogue JR, Thakur A, Cota MF, Zannikou M, Misener S, Krymskaya VP, McCortney K, Miska J, Horbinski C, Simberg D, Lesniak MS, James CD, Stupp R, Balyasnikova IV. Fully Humanized Bispecific T Cell Engager Shows Potent Activity in Central Nervous System and Peripheral Tumors. Adv Sci (Weinh). 2026 Jun; 13(35):e22391.
-
Sekrecki M, Sekrecka A, Lattupally RR, Le K, Jin X, Mozes C, Dwyer BG, Zhuang Z, Romero BA, Pineda JMB, Cao X, Nguyen L, Chen V, Zhou CM, Wallace JA, Tanaka K, Tiwari C, Gabel A, Kim WJ, Stanley RF, Benbarche S, Thind J, Muruganandham A, Zhang TY, Greenberg PL, Gotlib JR, Mannis G, Shomali WE, Salmasi G, Kuo C, Shanafelt T, Singh I, Inoue D, Hansen FK, Gray NS, van Rechem C, Fakhri B, Zhang X, Lu SX. Oncogenic SF3B1 mutations alter the splicing of mRNA noncoding regions to induce a novel therapeutic vulnerability. Blood. 2026 Apr 23; 147(17):1941-1957.
-
Bidany-Mizrahi T, Maroun K, Mancini M, Hidmi O, Ansari I, Monin J, Keidar Haran T, Maly A, Melino G, Candi E, Aqeilan RI. WWOX maintains epidermal identity and suppresses EMT to prevent aggressive cutaneous squamous cell carcinoma. Proc Natl Acad Sci U S A. 2026 Apr 21; 123(16):e2534844123.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|